Kategori: Nyheter

Kampanj för dagen för sällsynta sjukdomar 2023

Join our campaign for Rare Disease Day! February 28th is Rare Disease Day, where the rare community comes together, finds support and raises awareness for rare diseases across the globe […]

Roche/ Genentech uppdaterar GENERATION HD2-studien

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis avslutar VIBRANT-HD-studien

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

International Huntington Association får en mycket generös donation

International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at […]

uniQure meddelade att de återupptar rekryteringen av patienter på den högre dosnivån i AMT-130-studien.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences meddelar en positiv uppdatering från fas 1b/2a SELECT-HD-studien med inledande resultat som indikerar att WVE-003 har ett allelselektivt mål för Huntingtons sjukdom

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure meddelar uppdatering av kohort med låg dos i klinisk fas I/II-studie av AMT-130 genterapi för behandling av Huntingtons sjukdom

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences uppdaterar resultaten från studierna

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Sammanfattning av medvetandemånaden i maj

May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different […]

Webinar - Utforska för Huntington: Dimitri Poffés äventyr i Latinamerika

To finish May Awareness Month in the most inspiring and hopeful way possible, the International Huntington Association and European Huntington Association had a webinar with Dimitri Poffé, a Huntington’s Disease […]